Maturation of alveolar bone following implantation of an rhGDF-5/PLGA composite into 1-wall intra-bony defects in dogs: 24-week histometric observations

Jung Chul Park, Ulf M.E. Wikesjö, Ki Tae Koo, Jung Seok Lee, Yong Tae Kim, Susanne D. Pippig, Patrizia Bastone, Chang Sung Kim, Chong Kwan Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective The aim of this study was to evaluate long-term (24 weeks) alveolar bone maturation following surgical application of recombinant human growth/differentiation factor-5 (rhGDF-5) in an injectable poly-lactide-co- glycolide-acid (PLGA) composite carrier using an established periodontal defect model. Methods Routine, bilateral, 4 × 5 mm (width × depth), 1-wall, critical-size, intra-bony periodontal defects were surgically created at the 2nd and 4th mandibular premolar teeth in 10 Beagle dogs. The animals were randomized to receive (split-mouth design; defect sites in the same jaw quadrant getting the same treatment) rhGDF-5/PLGA high dose (188 μg/defect) versus sham-surgery control (5 animals), and rhGDF-5/PLGA low dose (37 μg/defect) versus carrier control (5 animals). The animals were euthanized for histometric analysis following a 24-week healing interval. Results Clinical healing was uneventful. The rhGDF-5 high dose significantly increased bone formation compared with controls in terms of bone area (p < 0.05), and a high degree of bone maturation was observed in the rhGDF-5/PLGA high dose group. Root resorption/ankylosis or other aberrant healing events were not observed. Conclusion The rhGDF-5/PLGA appears to support alveolar bone healing/regeneration and the rhGDF-5/PLGA high dose uniquely increased maturation of the regenerated bone.

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalJournal of Clinical Periodontology
Volume39
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Periodontics

Cite this